Initial Therapeutics

About:

Initial Therapeutics is a developer of small-molecule medicines designed to prevent pathogenic protein synthesis.

Top Investors: Apple Tree Partners

Description:

Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.

Total Funding Amount:

$78.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2020-01-01

Founders:

Brian Paegel, Jamie Cate, Kevan Shokat, Spiros Liras

Number of Employees:

11-50

Last Funding Date:

2023-05-01

IPO Status:

Private

Industries: